NuView Life Sciences is a clinical-stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView’s NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo confirmation of cancer. The NV-VPAC1 agent can deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.
Looking for a particular NuView Life Sciences, Inc employee's phone or email?
The NuView Life Sciences, Inc annual revenue was $1 million in 2026.
Paul Crowe is the Chairman and CEO of NuView Life Sciences, Inc.
3 people are employed at NuView Life Sciences, Inc.
NuView Life Sciences, Inc is based in Park City, Utah.
The NAICS codes for NuView Life Sciences, Inc are [541, 54, 62151, 621, 5417, 6215, 54171, 541712, 62].
The SIC codes for NuView Life Sciences, Inc are [87, 873].